S. Res. 614 is a nonbinding Senate resolution that designates February 2026 as “American Heart Month,” reasserts the United States’ interest in combating cardiovascular disease (CVD), and encourages public awareness, research, and improved access to care.
The text compiles recent CVD statistics, lists major risk factors, and asks individuals, organizations, and governments to observe the month.
The bill does not authorize funding or create regulatory obligations; instead it signals Congressional support for existing public-health activities (for example by the National Heart, Lung, and Blood Institute and nonprofit groups) and explicitly recognizes COVID–19’s lingering influence on cardiovascular outcomes. For stakeholders, the resolution functions as political and public-communications cover but not as a legal or fiscal mandate.
At a Glance
What It Does
The resolution formally names February 2026 as American Heart Month and contains six 'Resolved' clauses: it designates the month, endorses the month’s goals, affirms commitments to awareness, research, and access to care, notes COVID–19 impacts, commends existing efforts, and encourages individuals to learn their CVD risk. It also cites the statutory convention asking the President to issue an annual proclamation under title 36.
Who It Affects
The text primarily affects federal and state public-health communicators, nonprofit cardiovascular organizations, research institutions, health systems that run awareness or screening campaigns, and the general public targeted by outreach campaigns. It does not impose new compliance duties on private-sector actors or create grant programs.
Why It Matters
Although ceremonial, the resolution consolidates epidemiological and economic figures into a single congressional statement that can be used to justify outreach, fundraising, and advocacy. For policy teams and compliance officers, it matters because the resolution clarifies Congressional priorities (awareness, research, access) without attaching funds, creating a signal that may shape agency messaging and stakeholder expectations for the year ahead.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
S. Res. 614 is a Senate resolution that designates February 2026 as American Heart Month and lays out Congress’s public-health messaging about cardiovascular disease.
The preamble collects recent data—mortality counts, cost estimates, and known risk factors—and the operative clauses make a series of declarative commitments: endorsing the month, supporting its goals, and highlighting promotion, research, and access to care. The resolution also explicitly flags the pandemic’s continuing effects on cardiovascular health and commends state and nonprofit activity around the issue.
The text is declaratory rather than prescriptive. It requests and reiterates the established practice under section 101(1) of title 36 that the President issue an annual proclamation designating February as American Heart Month, but it does not create any new legal duties, appropriation authorities, or penalties.
Practically, that means agencies and organizations can treat the resolution as a policy signal that strengthens public messaging and advocacy plans but cannot assume it brings new funding or regulatory changes.The preamble’s statistics are specific and could be useful in grant proposals, media outreach, and strategic planning: the bill cites high-year mortality figures, multi-hundred-billion-dollar cost estimates, and enumerates eight major risk factors from high blood pressure to diabetes. Because the resolution links awareness, screening, and research to reducing long-term disability and mortality, organizations involved in cardiovascular screening, maternal health, congenital heart disease, and post–COVID care can reasonably expect this language to be invoked in communications and partnership requests during February 2026.Finally, while the resolution encourages individuals to learn their CVD risk and commends ongoing campaigns such as National Wear Red Day, it leaves implementation to states, nonprofits, clinics, and federal agencies operating within existing budgets.
That creates opportunities for advocacy groups to leverage Congressional attention for fundraising or cooperative campaigns, but it also leaves open the question of who will measure outcomes or coordinate a national response beyond awareness activities.
The Five Things You Need to Know
The resolution designates February 2026 specifically as “American Heart Month” and contains six operative clauses urging awareness, research, and access improvements.
The preamble lists eight explicit CVD risk factors (high blood pressure, high blood cholesterol, poor diet, tobacco use, physical inactivity, insufficient/poor-quality sleep, obesity, and diabetes mellitus).
S. Res. 614 cites concrete statistics from recent years: it reports over 919,000 CVD deaths in 2023 and cites a $417 billion estimate for 2020–2021 health care expenditures and lost productivity tied to heart disease.
The resolution references section 101(1) of title 36, reiterating the conventional request that the President issue an annual proclamation designating February as American Heart Month.
The text recognizes COVID–19’s influence on cardiovascular health and explicitly urges attention to the pandemic’s long-term implications for CVD and mortality rates.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Factual findings and context
The preamble compiles epidemiological and economic findings that frame the rest of the resolution: mortality totals, comparative death rates versus cancer and respiratory disease, trend data showing recent increases, and projected cost burdens through 2035. It also lists eight enumerated risk factors and highlights specific populations—maternal patients and infants with congenital heart defects—where CVD is a leading cause of death. For advocates, these findings are a ready-made, Congress-endorsed set of talking points; for agencies, they provide context but no programmatic direction.
Designation of American Heart Month
This clause formally designates February 2026 as American Heart Month. The effect is purely symbolic: it signals Congressional recognition and provides an official reference for federal and nonfederal entities to coordinate observances, press releases, and events in that month. The clause itself does not create appropriations or regulatory obligations.
Support for goals and ideals of the month
The Senate declares support for the aims associated with American Heart Month—awareness, prevention, and education. Practically, this is an endorsement that organizations can cite when applying for funding or seeking partnerships, but it contains no directive language mandating action by federal agencies or private parties.
Affirmation of priorities: awareness, research, access
This multipart clause recognizes three policy priorities: promoting awareness about causes and prevention, supporting research on CVD, and improving access to affordable, quality care to reduce long-term disability and mortality. Each is aspirational: 'supporting research' is not tied to specific grant mechanisms or budget authorities, and 'improving access' is a policy goal rather than a statutory change. The clause sets a clear agenda that advocacy groups can use to press agencies and appropriators for concrete follow-through.
Acknowledgement of COVID–19 impacts
The Senate specifically recognizes that the COVID–19 pandemic has long-term implications for cardiovascular health and mortality trends. By doing so, the resolution invites attention to post–COVID cardiovascular research and clinical monitoring; however, it stops short of recommending particular studies or authorizing funding for long-COVID cardiac programs.
Commendation and individual encouragement
These clauses commend states, territories, nonprofits, businesses, and individuals active in heart-health campaigns, and they encourage every person to learn their own CVD risk. The practical impact is mainly rhetorical: public-health campaigns and community organizations receive formal recognition, and clinicians and health systems may see increased demand for risk-assessment services during February without corresponding federal funding or directives.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Nonprofit cardiovascular organizations (e.g., American Heart Association) — the resolution amplifies their messaging and can be used in fundraising and awareness campaigns without requiring legislative change.
- Public-health departments at state and local levels — the designation provides a federally recognized window for outreach and partnership with private and nonprofit sectors.
- Researchers and academic institutions studying CVD and post–COVID cardiac outcomes — the resolution’s explicit support for research strengthens advocacy for grant applications and program visibility.
- Maternal and pediatric health advocates — the preamble’s focus on maternal CVD and congenital heart defects elevates these subfields in public communications and policy conversations.
- Health communications and employer wellness programs — the month designation creates a predictable period for screening drives, educational initiatives, and workplace campaigns.
Who Bears the Cost
- State and local public-health agencies — they may absorb operational costs for observances, screenings, and outreach within existing budgets, since the resolution does not provide new funding.
- Nonprofit organizations running campaigns — groups will likely shoulder marketing and event expenses to capitalize on Congressional recognition, increasing fundraising pressure.
- Health systems and clinics — an uptick in requests for risk assessment or screening during the month can create scheduling and staffing pressures without additional reimbursement.
- Federal agencies referenced (e.g., NIH, NHLBI) — agencies may need to prioritize staff time to coordinate messaging or technical assistance, again within current appropriations.
- Employers running wellness programs — businesses that decide to amplify activities during the month may incur programmatic and administrative costs.
Key Issues
The Core Tension
The central tension is between symbolic federal recognition (which can mobilize attention and private action quickly) and the absence of concrete funding, accountability, or programmatic direction; the resolution declares what should be done—awareness, research, access—without creating the fiscal or administrative mechanisms needed to ensure those outcomes.
S. Res. 614 is declaratory: it contains findings and aspirational directives but creates no enforceable obligations, authorizations, or appropriations.
That structure solves one problem—rapidly putting Congress on record about CVD—while creating another: stakeholders will expect follow-on action without a statutory mechanism to deliver it. The resolution’s language urging 'support' for research and 'improving access' is useful politically but vague operationally; agencies and appropriators would need separate statutory or budgetary action to turn these aspirations into programs or funding.
The bill also highlights equity and pandemic-related complications (for example, slower progress for some racial and ethnic groups and COVID–19’s influence on cardiovascular outcomes) but does not set metrics, targets, or responsibilities for addressing those issues. That raises practical questions about accountability: who measures whether the designation leads to reductions in mortality or disparities, and which entity is responsible for coordination?
Finally, by packaging a detailed set of statistics and risk factors into a symbolic resolution, Congress provides advocacy tools to many actors—but without guidance on evidence-based interventions to prioritize, the risk of scattered or duplicative activities increases.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.